Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL), a clinical-stage biopharmaceutical firm, will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, from 8:45 to 9:25 am ET. Founder and CEO Dr. William (Wei) Cao will lead the presentation. The webcast will be available via the company's investor website. Additionally, one-on-one meetings will occur from April 12-15, featuring Dr. Cao and CFO Dr. Kevin Xie. Gracell is focused on developing innovative cell therapies with its FasTCAR and TruUCAR technology platforms, addressing challenges in CAR-T therapies.

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will present at the 20^th Annual Needham Virtual Healthcare Conference (details below).

Corporate Presentation: 8:45 – 9:25 am ET, Monday, April 12, 2021
Presenter: Dr. William (Wei) Cao, Founder and CEO
Webcast: https://wsw.com/webcast/needham107/grcl/2238544
The webcast and replay of the presentation can also be accessed through the “News and Events” section of the Gracell Investor website.

One-on-one meetings: April 12-15, 2021
Management participants: Dr. William (Wei) Cao, Founder and CEO; Dr. Kevin Xie, CFO

For more information, please contact your Needham representative.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Media Contact
Marvin Tang
marvin.tang@gracellbio.com

Investor Contact
Gracie Tong
Gracie.tong@gracellbio.com

FAQ

When is Gracell's presentation at the Needham Virtual Healthcare Conference?

Gracell will present at the Needham Virtual Healthcare Conference on April 12, 2021, from 8:45 to 9:25 am ET.

Who will present on behalf of Gracell at the conference?

Dr. William (Wei) Cao, the Founder and CEO of Gracell, will present at the conference.

How can I access Gracell's presentation webcast?

The webcast for Gracell's presentation can be accessed through their investor website.

What are Gracell's technological platforms?

Gracell uses the FasTCAR and TruUCAR technology platforms to develop cell therapies.

What is the purpose of Gracell's one-on-one meetings?

The one-on-one meetings from April 12-15, 2021, will provide investors an opportunity to engage with management.

What challenges does Gracell's technology aim to address?

Gracell's technology aims to overcome challenges such as lengthy manufacturing times and high costs associated with CAR-T therapies.